Alkermes Plc Stock Today
| ALKS Stock | USD 29.32 0.07 0.24% |
Performance2 of 100
| Odds Of DistressLess than 1
|
Alkermes Plc is selling for under 29.32 as of the 28th of November 2024; that is 0.24 percent increase since the beginning of the trading day. The stock's lowest day price was 28.63. Alkermes Plc has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Alkermes Plc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of July 1991 | Category Healthcare | Classification Health Care |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. The company has 161.8 M outstanding shares of which 16.12 M shares are presently shorted by private and institutional investors with about 8.97 trading days to cover. More on Alkermes Plc
Moving against Alkermes Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alkermes Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman and CEO | Richard Pops | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, SP Small-Cap 600, ARCA Pharmaceutical, ARCA Biotechnology, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlkermes Plc can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alkermes Plc's financial leverage. It provides some insight into what part of Alkermes Plc's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkermes Plc (ALKS) is traded on NASDAQ Exchange in USA. It is located in Connaught House, Dublin, Ireland, D04 C5Y6 and employs 2,100 people. Alkermes Plc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.73 B. Alkermes Plc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 161.8 M outstanding shares of which 16.12 M shares are presently shorted by private and institutional investors with about 8.97 trading days to cover.
Alkermes Plc currently holds about 580.97 M in cash with 401.35 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54.
Check Alkermes Plc Probability Of Bankruptcy
Ownership AllocationThe majority of Alkermes Plc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alkermes Plc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alkermes Plc. Please pay attention to any change in the institutional holdings of Alkermes Plc as this could imply that something significant has changed or is about to change at the company.
Check Alkermes Ownership Details
Alkermes Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Deep Track Capital, Lp | 2024-09-30 | 3.5 M | |
| Primecap Management Company | 2024-09-30 | 3.3 M | |
| American Century Companies Inc | 2024-09-30 | 3.2 M | |
| Commodore Capital Lp | 2024-09-30 | 2.9 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.9 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 2.4 M | |
| Norges Bank | 2024-06-30 | 2.1 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 2.1 M | |
| Bank Of America Corp | 2024-06-30 | 2 M | |
| Blackrock Inc | 2024-06-30 | 29.1 M | |
| Vanguard Group Inc | 2024-09-30 | 19 M |
Alkermes Plc Historical Income Statement
Alkermes Stock Against Markets
Alkermes Plc Corporate Management
| Peter Norman | Senior Relations | Profile | |
| Iain Brown | Chief Accounting Officer | Profile | |
| Blair Jackson | Executive Officer | Profile | |
| Declan OConnor | Health Environment | Profile | |
| Samuel Parisi | Interim Finance | Profile |
Already Invested in Alkermes Plc?
The danger of trading Alkermes Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alkermes Plc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alkermes Plc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alkermes Plc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.